MA24169A1 - Traitement de l'asthme a l'aide de la tnfr-ig - Google Patents

Traitement de l'asthme a l'aide de la tnfr-ig

Info

Publication number
MA24169A1
MA24169A1 MA24590A MA24590A MA24169A1 MA 24169 A1 MA24169 A1 MA 24169A1 MA 24590 A MA24590 A MA 24590A MA 24590 A MA24590 A MA 24590A MA 24169 A1 MA24169 A1 MA 24169A1
Authority
MA
Morocco
Prior art keywords
tnfr
asthma
treatment
Prior art date
Application number
MA24590A
Other languages
English (en)
Inventor
Martin Renzetti Louis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA24169A1 publication Critical patent/MA24169A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA24590A 1996-05-08 1997-05-02 Traitement de l'asthme a l'aide de la tnfr-ig MA24169A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
MA24169A1 true MA24169A1 (fr) 1997-12-31

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24590A MA24169A1 (fr) 1996-05-08 1997-05-02 Traitement de l'asthme a l'aide de la tnfr-ig

Country Status (15)

Country Link
EP (1) EP0910413A2 (fr)
JP (1) JP2000510113A (fr)
KR (1) KR20000010825A (fr)
CN (1) CN1233189A (fr)
AR (1) AR007020A1 (fr)
AU (1) AU725408B2 (fr)
BR (1) BR9708928A (fr)
CA (1) CA2253557A1 (fr)
CO (1) CO4820397A1 (fr)
HR (1) HRP970224A2 (fr)
MA (1) MA24169A1 (fr)
PE (1) PE70698A1 (fr)
TR (1) TR199802238T2 (fr)
WO (1) WO1997041895A2 (fr)
ZA (1) ZA973843B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2316545A1 (fr) * 1997-12-29 1999-07-08 Regeneron Pharmaceuticals, Inc. Nouvel acide nucleique et nouveau polypeptide
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EA009079B1 (ru) * 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
EP3488851A1 (fr) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (fr) * 1993-03-29 1994-09-30 David Banner Muteines du facteur de necrose tumoral
JPH09508140A (ja) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
KR20000010825A (ko) 2000-02-25
WO1997041895A2 (fr) 1997-11-13
JP2000510113A (ja) 2000-08-08
CA2253557A1 (fr) 1997-11-13
BR9708928A (pt) 2000-05-09
AR007020A1 (es) 1999-10-13
AU2776497A (en) 1997-11-26
EP0910413A2 (fr) 1999-04-28
HRP970224A2 (en) 1998-04-30
WO1997041895A3 (fr) 1998-03-12
AU725408B2 (en) 2000-10-12
CO4820397A1 (es) 1999-07-28
TR199802238T2 (xx) 1999-02-22
CN1233189A (zh) 1999-10-27
PE70698A1 (es) 1998-11-18
ZA973843B (en) 1997-11-10

Similar Documents

Publication Publication Date Title
EP0754042A4 (fr) Traitement de l'atherosclerose
FR2727857B1 (fr) Prothese totale d'epaule
DZ2396A1 (fr) Traitement de l'eau
AU3590897A (en) Traveler's quarters
FR2735198B1 (fr) Piece d'accastillage de type manille-cosse
FR2739018B1 (fr) Prothese totale trochitero-acromiale de l'epaule
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
FR2644448B1 (fr) Installation de bassins d'epuration
FR2727855B1 (fr) Implants d'extension caverneuse
FR2754816B1 (fr) Procede de purification d'hydrogenochlorofluoroethanes
FR2740325B1 (fr) Prothese de l'articulation femoro-patellaire
EP0800396A4 (fr) Traitement d'etats d'hyperandrogenie
MA24411A1 (fr) Muteines de l'obesite
EP0981545A4 (fr) Traitement de l'osteoporose
ITMI932343A1 (it) Procedimento per l'isolamento e la purificazione di mevinolina
KR960038660U (ko) 브라운관의 반전이재기
FR2737894B1 (fr) Procede de preparation de fluorures d'alkyletain
KR960028334U (ko) 남성용 샤워기
FR2735986B3 (fr) Prolongateur d'haltere
EP0769488A3 (fr) Procédé pour la préparation du chloro-3-nitro-3'-méthoxy-4'-benzophénone
KR960003665U (ko) 착즙기의 걸름망 보강구조
KR960038365U (ko) 피엘씨의 입출력 증설장치
AU126026S (en) Hand's free dog walker
IT1279362B1 (it) Caldaia particolarmente per l'utilizzazione di scarti di lavorazione
ITTO940810A0 (it) "sedia"